Skip to Content
Merck
  • Supraspinal-selective TRPV1 desensitization induced by intracerebroventricular treatment with resiniferatoxin.

Supraspinal-selective TRPV1 desensitization induced by intracerebroventricular treatment with resiniferatoxin.

Scientific reports (2017-10-01)
Akihiro Fukushima, Kizuku Mamada, Aki Iimura, Hideki Ono
ABSTRACT

The transient receptor potential vanilloid type 1 (TRPV1) is a thermosensitive cation channel that triggers heat pain in the periphery. Long-term desensitization of TRPV1, which can be induced by excess amounts of agonists, has been a method for investigating the physiological relevance of TRPV1-containing neuronal circuits, and desensitization induced by various routes of administration, including systemic, intrathecal and intraganglionic, has been demonstrated in rodents. In the present study, we examined the effect of intracerebroventricular (i.c.v.) treatment with an ultrapotent TRPV1 agonist, resiniferatoxin (RTX), on nociception and the analgesic effect of acetaminophen, which is known to mediate the activation of central TRPV1. I.c.v. administration of RTX a week before the test did not affect the licking/biting response to intraplantar injection of RTX (RTX test), suggesting that such i.c.v. treatment spares the function of TRPV1 at the hindpaw. Mice that had been i.c.v.-administered RTX also exhibited normal nociceptive responses in the formalin test and the tail pressure test, but acetaminophen failed to induce analgesia in those mice in any of the tests. These results suggest that i.c.v. administration of RTX leads to brain-selective TRPV1 desensitization in mice.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Capsazepine, ≥98% (HPLC), solid